

HemoGenyx Pharmaceuticals

01:30 29 Jan 2019

Hemogenyx Pharma resetting the bar in blood cancers

HemoGenyx Pharmaceuticals PLC (LON:HEMO) is developing novel therapies for blood cancers that are safer and easier to tolerate than current standard of care treatments.

Two products are at pre-clinical stage: Immunotherapy product (CDX Ab) for patient conditioning and a cell therapy (Hu-PHEC) for bone-marrow transplants.

A clinical trial for the CDX antibody platform is being targeted for 2019.

What it does

Hemogenyx has three products under development:

CDX Bi-specific Antibodies (CDX Ab): Aims to redirect the patient's own immune cells to selectively target blood stem cells and certain types of blood cancer cells.

They could be used as a direct therapy to eliminate diseased cells or to clear unwanted blood stem cells prior to transplantation.

AHC Mouse Model: Hemogenyx has developed a novel humanised mouse model which the company believes exhibits a near fully-functional human immune system. Known as advanced hematopoietic chimeras (AHC), these mouse models may enable improved evaluation of therapies prior to entering expensive human trials.

Hemogenyx aims to form income-generating collaborations with biopharma companies and academic institutions who want to use the company's proprietary animal models to evaluate their own drug candidates, says Northland.

Hu-PHEC cell therapy: Utilises Hu-PHEC, a naturally-occurring type of cell, that can be collected and modified to generate cancer-free, own-patient blood stem cells, which can be used in bone marrow transplantation.

What the broker says

Northland: "Although the company has demonstrated strong progress across its pipeline, the share price remains below its IPO price of 3.5p/share. With multiple collaboration agreements and investment from industry we view the company as undervalued."

Blue Sky

Price: 3.075p

Market Cap: £11.11M

1 Year Share Price Graph



Share Information

Code: HEMO

Listing: LSE

52 week High Low
3.90p 1.80p

Sector: Nonequity Investment Instruments

Website: www.hemogenyx.com

Company Synopsis:

HemoGenyx Pharmaceuticals PLC. is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned US operating subsidiary, HemoGenyx LLC, located in Brooklyn, New York at its state-of-the-art research facility ("HemoGenyx"). For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases.

Author:

Proactive Investors Australia

+61 (0)2 9280 0700

action@proactiveinvestors.com.au

Total US market for bone marrow transplants US\$3bn-4bn and in Europe US\$5bn.

Hemogenyx's products offer the opportunity for more people to receive marrow transplants.

The humanised mouse model currently is generating significant interest from industry as an in-vivo platform for disease modelling and drug development, even though it was developed ostensibly as an in-house tool.

Many collaborations with biopharma are ongoing, including a US\$1mln investment from US group Orgenesis (NASDAQ:ORGS).

Inflection points

Filing of an IND application to the FDA regarding the CDX antibody platform to permit clinical trials.

Orphan Drug Designation by the FDA for the use of CDX Ab in BMT.

Pre-clinical data from Hu-PHEC cell therapy platform.

New contracts for AHC mouse model system.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.